OR WAIT null SECS
Vallerie McLaughlin, MD, is a professor of medicine and director of the Pulmonary Hypertension Program in the Division of Cardiovascular Medicine at the University of Michigan.
October 28, 2026
Video
The panel closes with practical changes clinicians can adopt immediately, including routine risk assessment, attention to the right heart, collaboration with expert centers, and an optimistic message for patients.
Echo findings can point toward precapillary or left heart physiology, but real patients often fall between categories. The panel debates integrated assessment versus choosing a lane for treatment.
New agents across established pathways are in development, while late diagnosis and underrepresented subgroups remain challenges. The panel also cautions that elevated hemodynamics alone do not make a diagnosis of PAH.
Regimen complexity, side effects, and unrealistic expectations drive nonadherence. The panel describes how open conversations, specialty pharmacy partnerships, and attention to quality of life support persistence.